| Pharmaceutical Information |
| Drug Name |
Oxtriphylline |
| Drug ID |
BADD_D01642 |
| Description |
Oxtriphylline is the choline salt form of [theophylline]. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). It is marketed under the name Choledyl SA, and several forms of oxytriphylline have been discontinued. In the US, oxtriphylline is no longer available. |
| Indications and Usage |
Used to treat the symptoms of asthma, bronchitis, COPD, and emphysema. |
| Marketing Status |
approved |
| ATC Code |
R03DA02 |
| DrugBank ID |
DB01303
|
| KEGG ID |
D02017
|
| MeSH ID |
C012839
|
| PubChem ID |
656652
|
| TTD Drug ID |
D0B0SH
|
| NDC Product Code |
Not Available |
| UNII |
3K045XR58X
|
| Synonyms |
cholinophyllin | oxtriphylline | choline theophyllinate | cholinetheophyllinate | Brondecon | Theobret | Choledyl-SA | Euspirax | oxtripylline-SA | Brondaxin | Choledyl |
|
| Chemical Information |
| Molecular Formula |
C12H21N5O3 |
| CAS Registry Number |
4499-40-5 |
| SMILES |
CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
